IFM Therapeutics raises $27M series A for immune modulators
IFM Therapeutics Inc. closed a $27 million series A financing led by Atlas Venture and Abingworth, with participation from Novartis AG. The Cambridge, Mass.-based company, incubated at Atlas, will use the financing to advance and expand its early stage portfolio of preclinical small-molecule modulators.
Outside of the US
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST